Silexion Posts $3.6M Q2 Loss and Cash Drops to $2.2M, Yet Nasdaq Equity Compliance Is Restored
SLXN is trading near its 52-week low of $0.411 (0.8% above the low).
Summary
Silexion reported a Q2 net loss of $3.6 million with cash down to $2.2 million, but a recent $2.5 million offering and estimated $3.2 million in equity restore Nasdaq compliance. The Phase 2/3 trial is now active at its first site.
Key Events · Earnings and Guidance · SLXN
-
Q2 Net Loss Widens to $3.6M
The Q2 2026 net loss reached $3.6 million, up 44% from $2.5 million a year ago, driven by a 120% increase in R&D expenses to $2.2 million as the company prepared for its Phase 2/3 trial.
-
Cash Position Drops to $2.2M
Cash and cash equivalents fell to $2.2 million as of June 30, 2026, from $6.0 million at December 31, 2025, reflecting heavy spending on clinical trial preparations.
-
Nasdaq Equity Compliance Restored
Following a $2.5 million public offering closed on August 13, 2026, the company estimates shareholders' equity at approximately $3.2 million, exceeding Nasdaq's $2.5 million minimum requirement.
-
Phase 2/3 Trial Initiated at First Site
The SIL204 Phase 2/3 trial in locally advanced pancreatic cancer was initiated at Tel Aviv Sourasky Medical Center on July 29, 2026, with patient screening underway and first dosing anticipated.
Analysis · SLXN · Life Sciences
The widening net loss in Q2 reflects a 120% surge in R&D spending as the company accelerates its Phase 2/3 pancreatic cancer trial. Cash has dwindled to $2.2 million from $6.0 million at year-end, but a $2.5 million public offering closed on August 13 and an estimated $3.2 million in shareholders' equity bring the company back into compliance with Nasdaq's minimum equity requirement. Additionally, the first clinical site was initiated in July, and new preclinical data support the potential for combination therapy.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 36.8% of the 982 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.68%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLXN was trading at $0.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $489K. The 52-week trading range was $0.41 to $80.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.